

PROTEXT PHARMA APPOINTS CHIEF PHARMACIST AS PART OF TEAM TO OVERSEE CANNABIS MEDICINE OPERATIONS UPON ISSUANCE OF ANTICIPATED LICENSE IN SOUTH AFRICA

FLORIDA, USA--(iHub –November 20th, 2017) – Protext Pharma, Inc. (PINKSHEETS: [TXTM](#)) ("Protext" or "the Company"), a biotech company engaged in the development of pharmaceutical botanical medicines that are formulated with highly-bioavailable plant extracts, today announced that it has appointed Mr. Tinus Lange to serve as a Chief Pharmacist for the company's South African subsidiary. Under regulations approved earlier this month by the South Africa Medicine Control Council (MCC), all applications for licenses to grow, process or distribute medical cannabis must engage a qualified pharmacist to oversee the operations. Mr. Lange's business information, pharmacy registration documents and security clearance, have been forwarded to the MCC as the final part of the Company's application for a medical cannabis license.

Mr. Lange is a highly regarded pharmacist in the Mpumalanga province of South Africa, having owned and operated his own pharmacy since 1985. He graduated with the Pharmacology degree in 1982 from North West University and co-developed the first dispensing program ever used in South African pharmacies. Pharmacology is a life-passion for Mr. Lange with both his wife and daughter also being certified pharmacists

Roger Baylis-Duffield, Chief Executive Officer of Protext Pharma, commented, "I am very pleased to have Mr. Lange's join our operations as Chief Pharmacist to oversee the development of our cannabis medicines platform once our license is issued. We will be working closely together to develop cannabis-based medicines that specifically address many of the disorders arising from the human endocannabinoid system. Being able to deliver a full-profile cannabis extract with up to 16 times the bioavailability of current extracts, while also being non-psychoactive, should give us a significant advantage in the marketplace. As with Plandaí's Phytofare[®] catechin complex, similar claims will be made with the cannabinoid complex through fact-based research and clinical trials. We intend to conduct clinical trials to determine the effectiveness of the Phytofare[®] cannabinoid extract in treating inflammation. Increasing evidence suggests that the endocannabinoid system, comprising cannabinoid receptors and their endogenous ligands and metabolic enzymes, can regulate inflammation in a wide variety of cells including osteoblasts and synovial fibroblasts. An estimated 52.5 million adults in the United States suffer from forms of arthritis, making it the single biggest cause of disability. Two of the most common forms of arthritis, osteoarthritis and rheumatoid arthritis are associated with pain and joint damage due to loss of surface cartilage and bone within synovial joints. Both conditions lead to a poor quality of life, the inability to perform everyday tasks and, ultimately, permanent joint damage."

Mr. Lang added, "This is a very exciting time in South Africa as just last Friday the MCC published a gazette officially changing their controlled substance schedule, down grading cannabidiol, when used for therapeutic purposes, from a schedule 6 drug to a schedule 4. I'm looking forward to working with the Company on developing its medical cannabis extract that I believe ultimately can help improve the quality of life of millions of people worldwide."

Once the anticipated license is issued, the Company intends to commence cannabis operations at a facility in the District of White River, South Africa, where plants will be grown, cloned and cultivated to ensure a consistent chemical profile. The facility will incorporate an on-site laboratory designed and engineered to process live flower and plant material and, after separation and recovery of the oil-phase as a separate income stream, the final stage will be specific to the production of the Phytofare[®] complex containing cannabinoids, cannabinoid acids, terpenes, limonene and polyphenols. The resulting complex will be subjected to product profiling, analysis and bioavailability in order to determine efficacy and dosage. The Company will use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD acids and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The Company's investigations will be designed to show that the our extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC

intact, resulting in a non-psychoactive extract (schedule 4) with full medicinal potential and having the heightened bioavailability of other Phytofare® extracts.

Investors are encouraged to follow Protex using:

YouTube: <http://bit.ly/ProtexYouTube>

Twitter: <https://twitter.com/protxtm>

Instagram: <https://www.instagram.com/protxtm/>

CONTACT INFORMATION

Info@protxtm.co

Contact: (435) 881-3611

About Protex Pharma, Inc.

Protex Pharma operates two wholly owned subsidiaries; Plandai Biotechnology South Africa (Pty) Ltd. and Cannabis Biosciences, Inc. The Company is engaged in the research, clinical testing and commercialization of highly bioavailable botanical products—all-natural ingredients formulated for pharmaceutical applications and produced under pharma-grade conditions. Please visit <http://www.protxtm.co> for further information.

About Plandai Biotechnology SA

Through its wholly owned subsidiary Plandai Biotechnology SA, the Company has the exclusive worldwide license to develop Phytofare® extracts from live plant materials including Phytofare® catechin complex, a highly bioavailable, and clinically proven antioxidant complex produced from live green tea leaves. Phytofare® can deliver a therapeutic level of catechins, which function as powerful antioxidants, to the system where they remain active for over 24 hours.

About Cannabis Biosciences

The Company is actively pursuing government licensing that will allow it to use its proprietary processing and extraction technology to commence investigations and produce a full-profile cannabis extract, one that contains both CBD and the precursor acid form of THC (THC-A and THC-B) found in live cannabis plant. The Company's investigations will be designed to show that the Cannabis Biosciences extraction process, which will use live leaf and low temperatures to extract the phyto-chemicals, should leave the acid forms of THC intact, resulting in a non-psychoactive extract with full medicinal potential and having the heightened bioavailability of other Phytofare® extracts.

Safe Harbor Statement

This release contains forward-looking statements that are based upon current expectations or beliefs, as well as a number of assumptions about future events. Although we believe that the expectations reflected in the forward-looking statements and the assumptions upon which they are based are reasonable, we can give no assurance or guarantee that such expectations and assumptions will prove to have been correct. Forward-looking statements are generally identifiable by the use of words like "may," "will," "should," "could," "expect," "anticipate," "estimate," "believe," "intend," or "project" or the negative of these words or other variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements, as these statements are subject to numerous factors and uncertainties, including but not limited to: adverse economic conditions, competition, adverse federal, state and local government regulation, international governmental regulation, inadequate capital, inability to carry out research, development and commercialization plans, loss or retirement of key executives and other specific risks. To the extent that statements in this press release are not strictly historical, including statements as to revenue projections, business strategy, outlook, objectives, future milestones, plans, intentions, goals, future financial conditions, events conditioned on stockholder or other approval, or otherwise as to future events, such statements are forward-looking, and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements contained in this release are subject to certain risks and

uncertainties that could cause actual results to differ materially from the statements made. The company disclaims any obligation to update information contained in any forward-looking statement. This press release shall not be deemed a general solicitation.